ResMed Q4 2020 Earnings Report
Key Takeaways
ResMed Inc. reported a 9% increase in revenue to $770.3 million for the fourth quarter of fiscal year 2020. Non-GAAP diluted earnings per share were $1.33, a 40% increase compared to the prior year period. The company saw strong sales across its mask product portfolio and increased demand for ventilators due to COVID-19.
Revenue increased by 9% to $770.3 million, or 10% on a constant currency basis.
GAAP diluted earnings per share were $1.22, while non-GAAP diluted earnings per share reached $1.33.
Net operating profit increased by 84%, with non-GAAP operating profit up by 24%.
The company supported the COVID-19 pandemic response through increased manufacturing of ventilators and ventilation mask systems.
ResMed
ResMed
ResMed Revenue by Segment
ResMed Revenue by Geographic Location
Forward Guidance
ResMed is confident in its ability to navigate through the ongoing challenging clinical and economic environment to deliver for all stakeholders. Sleep labs and physician practices are reopening across many geographies, and the company is seeing accelerated adoption of digital health solutions which supports its long-term strategy.
Positive Outlook
- Sleep labs and physician practices are reopening across many geographies.
- Accelerated adoption of digital health solutions.
- Strong foundation to accelerate growth over the longer term.
- Increased manufacturing of ventilators.
- Supporting customers with digital health solutions.
Challenges Ahead
- Ongoing challenging clinical and economic environment.
- Uncertain environment.
- Declines in manufacturing and procurement efficiencies driven by higher air freight costs.
- Impact of legal settlement expenses in the prior year.
- COVID-19 pandemic.
Revenue & Expenses
Visualization of income flow from segment revenue to net income